CMS Announces Savings for Seniors on 15 Major Drugs

On Nov. 25, 2025, the Centers for Medicare & Medicaid Services (CMS) announced a net savings of 44%, or $12 billion, from last year's negotiated Medicare spending on 15 drugs used widely to treat cancer and other serious chronic conditions.

The Maximum Fair Prices (MFPs) for these 15 drugs will become effective January 1, 2027, bringing the total number of negotiated drugs to 25 when combined with the 10 previously negotiated drugs with MFPs that took effect January 1, 2026.

The 15 drugs in this second negotiation cycle, used to treat cancer, diabetes, asthma and other chronic illnesses, represent some of the highest Medicare Part D spending.

The drugs include Ozempic, Rybelsus, Wegovy, Trelegy Ellipta, Pomalyst, Ofev, Ibrance, Linzess, Calquence, Otezla, Vraylar, Tradjenta, and Janumet.